Literature DB >> 3744135

Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers.

D Lockner, G Bratt, E Törnebohm, W Aberg.   

Abstract

Studies in 8 healthy volunteers showed that the low molecular weight heparin Fragmin KabiVitrum is eliminated according to first order kinetics without dose dependency after intravenous injection of doses between 40 and 120 anti-Xa U/kg. Fragmin remains in the circulation more than twice as long as unfractionated heparin (UFH). Fragmin administered subcutaneously has a bioavailability which is much greater than that of UFH. Fragmin administered subcutaneously twice a day results in a significant anti-Xa activity and provides an alternative to intravenous infusions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3744135     DOI: 10.1159/000215349

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  4 in total

Review 1.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

2.  Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

Authors:  G F Handeland; U Abildgaard; H A Holm; K E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Low molecular weight heparin in prevention of perioperative thrombosis.

Authors:  A Leizorovicz; M C Haugh; F R Chapuis; M M Samama; J P Boissel
Journal:  BMJ       Date:  1992-10-17

Review 4.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.